As the world’s pharmaceutical industry continues its recent spree of mergers and acquisitions, the consolidation seems to continue with AbbVie’s latest attempt to acquire one of its competitors.
The US pharmaceutical firm just raised its offer to purchase UK-based rival Shire to about $51 billion after an earlier offer was rejected. Reports say the initial bid amounted to about $46 billion.
AbbVie is reportedly looking to purchase the UK firm to reduce its tax burden and shift its finances overseas. AbbVie is also seeking out its next business ventures as its top-selling product, Humira, is set to lose its patent protection in 2016. Humira accounts for nearly 60 percent of the company’s revenue, reports say, and is the world’s top selling drug.
Full content: CNBC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Turkey Fines Meta $10.4 Million for Abusing Market Dominance
May 6, 2024 by
CPI
Canadian Watchdog Launches Inquiry into Lululemon’s Greenwashing Practices
May 6, 2024 by
CPI
Massachusetts Supreme Court Deliberates Ballot Redefining Gig Worker Status
May 6, 2024 by
CPI
European Commission Approves Nippon Steel’s $14.9 Billion Buyout of U.S. Steel
May 6, 2024 by
CPI
Banco Sabadell Rejects Rival BBVA Merger Proposal
May 6, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI